sarcoma

This page shows the latest sarcoma news and features for those working in and with pharma, biotech and healthcare.

Nanobiotix signs €40m deal with the EIB

The candidate just hit its primary endpoint in a Phase II/III trial in soft tissue sarcoma (STS).

AstraZeneca expands alliance with Bicycle Therapeutics

The peptide portion of BT1718 binds to MT1-MMP, which is highly expressed in many solid tumours, including triple negative breast cancer, sarcoma and non-small cell lung cancer, and is
Merck forges closer ties with Cancer Research UK

notable pipeline failures, including evofosfamide for advanced soft tissue sarcoma and pancreatic cancer.
Bayer gets clinical data to support $1.5bn Loxo deal

uncontrolled cellular growth that is evident in a wide range of tumours, including infantile fibrosarcoma, thyroid cancer and various soft tissue sarcomas, but collectively account for less than 1% of all
Loxo’s cancer drug pair attracts $1.5bn deal with Bayer

They are seen in a collection of malignancies including colorectal adenocarcinoma, soft tissue sarcoma, infantile fibrosarcoma and cholangiocarcinoma.
Avelumab costs peg back profit at Merck KGaA

sarcoma and pancreatic cancer after phase III study failures.

More from news
Approximately 5 fully matching, plus 38 partially matching documents found.

Europe vs the US: New drug product approvals

Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),
Case study: Treatment guidance

The Practical Guide was launched as part of a Takeda sponsored symposium at the British Sarcoma Group’s annual conference.
Pharma deals during February 2014

Also, this month Merck &Co has handed back the rights to Ariad Pharmaceutical's ridaforolimus, a mTOR inhibitor in a phase III trial for advanced sarcoma.
Interview: Harvey Berger and Timothy Clackson, Ariad

And that was absolutely correct.”. After selling off investigational sarcoma treatment ridaforolimus to Merck &Co following an aborted collaboration attempt, ponatinib emerged as the front-runner in the company's pipeline

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

World AIDS Day 2018: Fighting the stigma surrounding HIV

2. Characterised by very low levels of CD4+ T cells, and the presence of AIDS-related pathologies (such as tuberculosis and Kaposi’s sarcoma), the diagnosis of AIDS marks just how

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Global Business Development Director – Health Education: excellent commission

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Add my company

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Unlocking the potential of science and technology in the UK: Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...